I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Paolicelli, Giuseppe
80
results:
Search for persons
X
Format
Online (80)
Mediatypes
Articles (Online) (37)
OpenAccess-fulltext (43)
Sorted by: Year
Sorted by: Relevance
?
1
Long-term effectiveness of natalizumab in secondary progres..:
Chisari, Clara G.
;
Aguglia, Umberto
;
Amato, Maria Pia
...
Neurotherapeutics. 21 (2024) 4 - p. e00363 , 2024
Link:
https://doi.org/10.1016/..
?
2
A comparison of natalizumab and ocrelizumab on disease prog..:
Iaffaldano, Pietro
;
Lucisano, Giuseppe
;
Guerra, Tommaso
...
Annals of Clinical and Translational Neurology. 11 (2024) 8 - p. 2008-2015 , 2024
Link:
https://doi.org/10.1002/..
?
3
Predicted Expenditure for Prescription Drugs for Multiple S..:
Paolicelli, Damiano
;
Borriello, Giovanna
;
Clerici, Raffaella
...
Neurology and Therapy. , 2024
Link:
https://doi.org/10.1007/..
?
4
A microbially produced AhR ligand promotes a Tph1-driven to..:
Zelante, Teresa
;
Paolicelli, Giuseppe
;
Fallarino, Francesca
...
Scientific Reports. 14 (2024) 1 - p. , 2024
Link:
https://doi.org/10.1038/..
?
5
Long-term effectiveness of natalizumab in secondary progres..:
Chisari, Clara G
;
Aguglia, Umberto
;
Amato, Maria Pia
...
info:eu-repo/semantics/altIdentifier/pmid/38714462. , 2024
Link:
https://hdl.handle.net/1..
?
6
COVID-19 outbreak in Italy: an opportunity to evaluate exte..:
Bisecco, Alvino
;
Matrone, Federica
;
Capobianco, Marco
...
info:eu-repo/semantics/altIdentifier/pmid/37982852. , 2024
Link:
https://hdl.handle.net/1..
?
7
Long-term effectiveness of natalizumab in secondary progres..:
Chisari, Clara G
;
Aguglia, Umberto
;
Amato, Maria Pia
...
info:eu-repo/semantics/altIdentifier/pmid/38714462. , 2024
Link:
https://hdl.handle.net/2..
?
8
Urinary epidermal growth factor/monocyte chemotactic peptid..:
Rocchetti, Maria Teresa
;
Pesce, Francesco
;
Matino, Silvia
...
Journal of Nephrology. 36 (2022) 4 - p. 987-997 , 2022
Link:
https://doi.org/10.1007/..
?
9
Neuromyelitis optica spectrum disorders associated with sys..:
Bollo, Luca
;
Santoro, Carlo
;
Libro, Giuseppe
...
Neurological Sciences. 43 (2022) 6 - p. 4015-4018 , 2022
Link:
https://doi.org/10.1007/..
?
10
Trajectories of disability and relapse-rate in naïve patien..:
Manni, Alessia
;
Paolicelli, Damiano
;
Lucisano, Giuseppe
...
Neurology. 98 (2022) 18_supplement - p. , 2022
Link:
https://doi.org/10.1212/..
?
11
Risk of Getting COVID-19 in People With Multiple Sclerosis:..:
Iaffaldano, Pietro
;
Lucisano, Giuseppe
;
Manni, Alessia
...
info:eu-repo/semantics/altIdentifier/pmid/35046084. , 2022
Link:
https://hdl.handle.net/1..
?
12
Risk of Getting COVID-19 in People With Multiple Sclerosis:..:
Iaffaldano, Pietro
;
Lucisano, Giuseppe
;
Manni, Alessia
...
info:eu-repo/semantics/altIdentifier/pmid/35046084. , 2022
Link:
https://hdl.handle.net/1..
?
13
Risk of Getting COVID-19 in People With Multiple Sclerosis:..:
Iaffaldano, Pietro
;
Lucisano, Giuseppe
;
Manni, Alessia
...
info:eu-repo/semantics/altIdentifier/pmid/35046084. , 2022
Link:
http://hdl.handle.net/11..
?
14
PML risk is the main factor driving the choice of discontin..:
Chisari, Clara G.
;
Comi, Giancarlo
;
Filippi, Massimo
...
Journal of Neurology. 269 (2021) 2 - p. 933-944 , 2021
Link:
https://doi.org/10.1007/..
?
15
Comparative effectiveness of early intensive or escalation ..:
Iaffaldano, Pietro
;
Lucisano, Giuseppe
;
Caputo, Francesca
...
Journal of the Neurological Sciences. 429 (2021) - p. 117749 , 2021
Link:
https://doi.org/10.1016/..
1-15